Matthieu Ruffin

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Annamaria Colao, Marcello D. Bronstein, Pamela U. Freda et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 394 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Michael C. Sheppard, Marcello D. Bronstein, Pamela U. Freda et al. · Pituitary · 2014 · 81 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +11

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

Marcello D. Bronstein, Maria Fleseriu, Sebastian Neggers et al. · BMC Endocrine Disorders · 2016 · 78 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +10

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Stephan Petersenn, Andrew J. Farrall, Christophe De Block et al. · Pituitary · 2013 · 59 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +13

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study

H. Dietrich, Ke Hu, Matthieu Ruffin et al. · European Journal of Endocrinology · 2012 · 35 citations

Pharmacy, Pharmacokinetics, Pharmacology +13